New FTC Commissioner’s Potential Impact on Healthcare Antitrust Review

Alvaro Bedoya’s confirmation has restored a Democratic majority on the Federal Trade Commission.  Under a Democratic majority, FTC Chair Khan has the ability to continue to further test novel theories of harm in both merger and non-merger matters generally and in healthcare in particular.  Additionally, Commissioner Bedoya’s background in privacy and technology could further broaden the scope of both merger and non-merger investigations.  We consider the potential scope of the